The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
Relmada’s major depression drug shows PhIII promise in a fresh batch of patients
Relmada Therapeutics’ once-daily REL-1017 has shown positive data in major depressive disorder (MDD) from a registrational Phase III trial, a year after an unexpected late-stage
September 21, 2023